Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,607.98 91.71 0.63%
TOPIX 1,178.17 4.80 0.41%
HANG SENG 22,760.24 64.23 0.28%

Trovagene to Present at 25th Annual Roth Conference



             Trovagene to Present at 25th Annual Roth Conference

Presentation scheduled on March 19, 2013 at 12:00 p.m. PT at the Ritz-Carlton
Laguna Nigel, in Dana Point, CA

PR Newswire

SAN DIEGO, March 12, 2013

SAN DIEGO, March 12, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a
developer of transrenal molecular diagnostics, today announced that Chief
Financial Officer Stephen Zaniboni is scheduled to present a corporate
overview at the 25^th Annual Roth OC Growth Stock Conference at the
Ritz-Carlton Laguna Nigel, in Dana Point, CA on Tuesday, March 19, 2013 at
12:00 p.m. Mr. Zaniboni will be available for one-on-one meetings during the
conference.

(Logo: http://photos.prnewswire.com/prnh/20120620/LA28014LOGO)

The presentation will be webcast live at http://wsw.com/webcast/roth27/trov/
and can also be accessed through the investor relations page at
www.trovagene.com. A replay of the presentation will be available at
www.trovagene.com and will be archived for 30 days.

About Trovagene, Inc.

Headquartered in San Diego, California, Trovagene is developing its patented
technology for the detection of transrenal DNA and RNA, short nucleic acid
fragments, originating from normal and diseased cell death that cross the
kidney barrier and can be detected in urine.  Trovagene is leveraging its
intellectual property in oncogene mutations via out-licensing and use of its
transrenal technologies to extend oncogene mutation detection using urine as a
sample.  As a non-invasive and abundant sample, urine may overcome many of the
cost and collection challenges associated with biopsy, as well as the volume
limitations of blood.

Trovagene has a strong patent position as it relates to transrenal molecular
testing. It has U.S. and European patent applications and issued patents that
cover testing for HPV and other infectious diseases, cancer, transplantation,
prenatal and genetic testing. In addition, it owns worldwide rights to
nucleophosmin-1 (NPM1), an informative biomarker for acute myelogenous
leukemia (AML) and mutations in the SF3B1 gene, which have been shown to be
associated with chemotherapy response in chronic lymphocytic leukemia (CLL)
patients, as well as other hematologic malignancies.

Certain statements in this press release are forward-looking within the
meaning of the Private Securities Litigation Reform Act of 1995. These
statements may be identified by the use of forward-looking words such as
"anticipate," "believe," "forecast," "estimated" and "intend," among others.
These forward-looking statements are based on Trovagene's current expectations
and actual results could differ materially. There are a number of factors that
could cause actual events to differ materially from those indicated by such
forward-looking statements. These factors include, but are not limited to,
substantial competition; our ability to continue as a going concern; our need
for additional financing; uncertainties of patent protection and litigation;
uncertainties of government or third party payer reimbursement; limited sales
and marketing efforts and dependence upon third parties; and risks related to
failure to obtain FDA clearances or approvals and noncompliance with FDA
regulations. As with any medical diagnostic tests under development, there are
significant risks in the development, regulatory approval and
commercialization of new products. There are no guarantees that future
clinical trials discussed in this press release will be completed or
successful or that any product will receive regulatory approval for any
indication or prove to be commercially successful. Trovagene does not
undertake an obligation to update or revise any forward-looking statement. 
Investors should read the risk factors set forth in Trovagene's Form 10-K for
the year ended December 31, 2011 and other periodic reports filed with the
Securities and Exchange Commission.

Contact

Trovagene, Inc.
Amy Caterina
Investor Relations
+1 (858) 952-7593
acaterina@trovagene.com
http://www.trovagene.com

SOURCE Trovagene, Inc.

Website: http://www.trovagene.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement